Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant prostate cancer (mCRPC) who have previously progressed on at least one prior androgen pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide).
Castrate Resistant Prostate Cancer|Metastatic Castration-resistant Prostate Cancer|Prostate Cancer|Prostate Carcinoma
DRUG: Pembrolizumab|DRUG: 177Lu-PSMA-617
Median radiographic progression-free survival (rPFS) at 12 months, rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic progression at 12 months from initiation of trial therapy will be reported along with the 95% confidence interval., 12 months
Overall median radiographic rPFS, rPFS is defined as the amount of time from initiation of study therapy until the participant experiences radiographic disease progression per RECIST v. 1.1 and PCWG3 criteria, initiates subsequent anti-cancer therapy, completes study participation, or experiences death from any cause (whichever is sooner). If disease progression or death from any cause is not observed prior to initiating subsequent anti-cancer therapy or completing study participation, the rPFS will be censored as the last available disease assessment. Participants who discontinue treatment for clinical progression or deterioration will be included in the analysis. Results will be reported in months, Up to 5 years|Objective response rate (ORR), The proportion of participants treated with both 177Lu-PSMA-617 and Pembrolizumab who experience an objective response defined as a confirmed complete response (CR) or confirmed partial response (PR) per RECIST v. 1.1 and PCWG3 criteria from the initiation of trial therapy until confirmed response, disease progression, initiation of subsequent anti-cancer therapy, or participant has completed study participation (whichever occurs first). Point estimate of objective response rate will be obtained along with its 95% confidence interval., Up to 10 months|Median duration of objective response (DOR), Duration of objective response is defined as the amount of time between the day of first documented response to trial therapy (confirmed CR or confirmed PR, whichever is first recorded) and subsequent disease progression (per RECIST v. 1.1 and PCWG3 criteria). Median duration of objective response will be calculated based on the using Kaplan-Meier product limit method., Up to 10 months|Proportion of participants with 50% decline in PSA (PSA50), The proportion of participants who achieve greater than 50% decline in baseline PSA (drawn at the initiation of trial therapy), at any point during the course of treatment., Up to 10 months|Proportion of participants with 90% decline in PSA (PSA90), The proportion of participants who achieve greater than 90% decline in baseline PSA (drawn at the initiation of trial therapy), at any point during the course of treatment., Up to 10 months|Median time to PSA progression (TTPP1) following the first dose of 177Lu-PSMA-617, TTPP1 is the amount of time from the date of first treatment with 177Lu-PSMA-617, to the date of the first PSA level meeting the definition for PSA progression per PCWG3 criteria., Up to 10 months|Proportion of participants with PSA50 following the first dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 50% decline in baseline PSA (drawn at the initiation of trial therapy), following the first dose of 177Lu-PSMA-617, Up to 10 months|Proportion of participants with PSA90 following the first dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 90% decline in baseline PSA (drawn at the initiation of trial therapy), following the first dose of 177Lu-PSMA-617, Up to 10 months|Median time to PSA progression (TTPP2) following the second dose of 177Lu-PSMA-617, TTPP2 is the amount of time from the date of the second treatment with 177Lu-PSMA-617, to the date of the first PSA level meeting the definition for PSA progression per PCWG3 criteria., Up to 10 months|Proportion of participants with PSA50 following the second dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 50% decline in baseline PSA (drawn at the initiation of trial therapy), following the second dose of 177Lu-PSMA-617, Up to 10 months|Proportion of participants with PSA90 following the second dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 90% decline in baseline PSA (drawn at the initiation of trial therapy), following the second dose of 177Lu-PSMA-617, Up to 10 months|Median time to PSA progression (TTPP3) following the third dose of 177Lu-PSMA-617, TTPP3 is the amount of time from the date of the third treatment with 177Lu-PSMA-617, to the date of the first PSA level meeting the definition for PSA progression per PCWG3 criteria., Up to 10 months|Proportion of participants with PSA50 following the third dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 50% decline in baseline PSA (drawn at the initiation of trial therapy), following the third dose of 177Lu-PSMA-617, Up to 10 months|Proportion of participants with PSA90 following the third dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 90% decline in baseline PSA (drawn at the initiation of trial therapy), following the third dose of 177Lu-PSMA-617, Up to 10 months|Median time to PSA progression (TTPP4) following the fourth dose of 177Lu-PSMA-617, TTPP4 is the amount of time from the date of the fourth treatment with 177Lu-PSMA-617, to the date of the first PSA level meeting the definition for PSA progression per PCWG3 criteria., Up to 10 months|Proportion of participants with PSA50 following the fourth dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 50% decline in baseline PSA (drawn at the initiation of trial therapy), following the fourth dose of 177Lu-PSMA-617, Up to 10 months|Proportion of participants with PSA90 following the fourth dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 90% decline in baseline PSA (drawn at the initiation of trial therapy), following the fourth dose of 177Lu-PSMA-617, Up to 10 months|Median time to PSA progression (TTPP5) following the fifth dose of 177Lu-PSMA-617, TTPP5 is the amount of time from the date of the fifth treatment with 177Lu-PSMA-617, to the date of the first PSA level meeting the definition for PSA progression per PCWG3 criteria., Up to 10 months|Proportion of participants with PSA50 following the fifth dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 50% decline in baseline PSA (drawn at the initiation of trial therapy), following the fifth dose of 177Lu-PSMA-617, Up to 10 months|Proportion of participants with PSA90 following the fifth dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 90% decline in baseline PSA (drawn at the initiation of trial therapy), following the fifth dose of 177Lu-PSMA-617, Up to 10 months|Median time to PSA progression (TTPP6) following the sixth dose of 177Lu-PSMA-617, TTPP6 is the amount of time from the date of the sixth treatment with 177Lu-PSMA-617, to the date of the first PSA level meeting the definition for PSA progression per PCWG3 criteria., Up to 10 months|Proportion of participants with PSA50 following the sixth dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 50% decline in baseline PSA (drawn at the initiation of trial therapy), following the sixth dose of 177Lu-PSMA-617, Up to 10 months|Proportion of participants with PSA90 following the sixth dose of 177Lu-PSMA-617, The proportion of participants who achieve greater than 90% decline in baseline PSA (drawn at the initiation of trial therapy), following the sixth dose of 177Lu-PSMA-617, Up to 10 months|Median overall survival (OS), OS is defined as the amount of time from the initiation of trial therapy until the date of death from any cause for all evaluable participants. Participants who discontinue from study follow up or are lost to follow up will be censored at the date of last contact. Median overall survival and 95% confidence interval will be estimated using the Kaplan-Meier method., Up to 5 years|Percentage of participants with reported treatment-emergent adverse events, Severity of the toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Adverse events (including immune-related adverse events) and clinically-significant laboratory abnormalities meeting Grade 3, 4, or 5 criteria according to CTCAE, will be summarized by maximum intensity and relationship to study drug., Up to 10 months
PRIMARY OBJECTIVE:

I. To determine the 12-month radiographic progression-free survival rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria in patients with mCRPC treated with pembrolizumab and 177Lu-PSMA-617.

SECONDARY OBJECTIVES:

I. To determine the median radiographic progression-free survival per RECIST v. 1.1 and PCWG3 criteria in patients with mCRPC treated with pembrolizumab and 177Lu-PSMA-617.

II. To determine the objective response rate per RECIST v. 1.1 and PCWG3 criteria in patients with mCRPC treated with pembrolizumab and 177Lu-PSMA-617.

III. To determine the median duration of objective response per RECIST v. 1.1 and PCWG3 criteria in patients with mCRPC treated with pembrolizumab and 177Lu-PSMA-617.

IV. To determine the greater than 50% decline from baseline PSA (PSA50) and greater than 90% decline from baseline PSA (PSA90) response rate by PCWG3 criteria at any time point on study, as well as individually following each dose of 177Lu-PSMA-617.

V. To determine the median time to PSA progression (TTPP) following each dose of 177Lu-PSMA-617 (e.g., TTPP-1, TTPP-2, etc.), as measured by PCWG3 criteria.

VI. To determine the median overall survival in patients with mCRPC treated with pembrolizumab and 177Lu-PSMA-617.

VII. To characterize the safety profile of the combination of pembrolizumab and 177Lu-PSMA-617 in patients with mCRPC.

EXPLORATORY OBJECTIVES:

I. To determine the lesion-specific response by baseline uptake on PSMA PET.

II. To determine the patterns of PSMA expression at the time of each TTPP event and at radiographic progression.

III. To further characterize the tumor microenvironment using Single-cell RNA sequencing (scRNA-seq) of paired metastatic tumor biopsies (a biopsy is required if there is an accessible lesion).

IV. To develop a biomarker predictive of durable response based on Cytometry by time of flight (CyTOF) profiling of whole blood samples collected at baseline and early time points on treatment.

V. To determine whether successive doses of 177Lu-PSMA-617 leads to ablation of effector T cells and up- regulation of myeloid cell states in the periphery and tumor microenvironment.

VI. To characterize participant reported outcomes using the Brief Pain Inventory and The Functional Assessment of Cancer Therapy - Prostate (FACT-P) instruments.

VII. To correlate the number of 177Lu-PSMA-617 re-priming doses and PSA progression events with radiographic rPFS.

VIII. To evaluate and compare the efficacy of 177Lu-PSMA-617 between the subgroup of participants who received a single dose of 177Lu-PSMA-617 followed by adaptive dosing, and the subgroup of participants who received two doses of 177Lu-PSMA-617 followed by adaptive dosing.

IX. To evaluate and compare efficacy between the subgroup of participants who received Schedule 1 versus Schedule 2 dosing.

X. To evaluate and compare efficacy between the subgroup of participants who have received prior taxane chemotherapy versus participants who were taxane-na√Øve at the time of study entry.

OUTLINE:

Participants will receive two doses of 177Lu-PSMA-617 and may continue treatment for up to a total of six total doses in the absence of unequivocal clinical progression, or unacceptable toxicity, with minimum interval of 6 weeks between doses. Participants will also receive pembrolizumab and may continue study treatment until unequivocal evidence of clinical progression or at physician's discretion based on clinical evaluation. Participants will undergo safety follow-up visits approximately 30 days and 90 days following the end of treatment visit. Participants will then be seen in clinic or contacted by telephone every 3 months to assess survival/disease/anti-cancer therapy status until death, withdrawal of consent, or the end of the study, whichever occurs first until study closure.